Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
Bajpai, R, Matulis, S M, Wei, C, Nooka, A K, Von Hollen, H E, Lonial, S, Boise, L H, Shanmugam, M
Published in Oncogene (28.07.2016)
Published in Oncogene (28.07.2016)
Get full text
Journal Article
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
Richardson, P G, Hofmeister, C C, Raje, N S, Siegel, D S, Lonial, S, Laubach, J, Efebera, Y A, Vesole, D H, Nooka, A K, Rosenblatt, J, Doss, D, Zaki, M H, Bensmaine, A, Herring, J, Li, Y, Watkins, L, Chen, M S, Anderson, K C
Published in Leukemia (01.12.2017)
Published in Leukemia (01.12.2017)
Get full text
Journal Article
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
Nooka, A.K., Nabhan, C., Zhou, X., Taylor, M.D., Byrtek, M., Miller, T.P., Friedberg, J.W., Zelenetz, A.D., Link, B.K., Cerhan, J.R., Dillon, H., Sinha, R., Shenoy, P.J., Levy, D., Dawson, K., Hirata, J.H., Flowers, C.R.
Published in Annals of oncology (01.02.2013)
Published in Annals of oncology (01.02.2013)
Get full text
Journal Article
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable
Nooka, AK, Costa, LJ, Gasparetto, CJ, Richardson, PG, Siegel, DS, Chari, A, Lentzsch, S, Jagannath, S, Mikhael, J.
Published in Clinical lymphoma, myeloma and leukemia (01.07.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.07.2022)
Get full text
Journal Article
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
Nooka, A K, Kaufman, J L, Muppidi, S, Langston, A, Heffner, L T, Gleason, C, Casbourne, D, Saxe, D, Boise, L H, Lonial, S
Published in Leukemia (01.03.2014)
Published in Leukemia (01.03.2014)
Get full text
Journal Article
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
Matulis, S M, Gupta, V A, Nooka, A K, Hollen, H V, Kaufman, J L, Lonial, S, Boise, L H
Published in Leukemia (01.05.2016)
Published in Leukemia (01.05.2016)
Get full text
Journal Article
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
Richardson, P. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S., Lonial, S., Laubach, J., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J., Doss, D., Zaki, M. H., Bensmaine, A., Herring, J., Li, Y., Watkins, L., Chen, M. S., Anderson, K. C.
Published in Leukemia (01.10.2018)
Published in Leukemia (01.10.2018)
Get full text
Journal Article
P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
Quach, H., Leleu, X., Mateos, M.‐V., Usmani, S. Z., Nooka, A. K., Goldrick, A., Najdi, R., Shu, N., Facon, T.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
PB2013: TECLISTAMAB COMPARED WITH REAL‐WORLD THERAPIES IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
Krishnan, A., Nooka, A. K., Chari, A., Garfall, A., Martin, T., Nair, S., Lin, X., Qi, K., Londhe, A., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Slavcev, M., Usmani, S.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors
DeFilipp, Z, Rosand, C B, Goldstein, D A, Master, V A, Carthon, B C, Harris, W B, Kucuk, O, Al-Kadhimi, Z, Cohen, J B, Flowers, C R, Lechowicz, M J, Nooka, A K, Kaufman, J L, Langston, A A, Chen, Z, Arora, J, Waller, E K
Published in Bone marrow transplantation (Basingstoke) (01.01.2017)
Published in Bone marrow transplantation (Basingstoke) (01.01.2017)
Get full text
Journal Article
P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING‐ADJUSTED INDIRECT TREATMENT COMPARISON
Delforge, M., Usmani, S. Z., Donk, N. W., Garfall, A. L., Moreau, P., Oriol, A., Nooka, A. K., Rosinol, L., Bahlis, N., Rodriguez‐Otero, P., Martin, T., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Krishnan, A.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐4 STUDY
Suvannasankha, A., Bahlis, N., Trudel, S., Weisel, K., Koenecke, C., Oriol, A., Voorhees, P. M., Alonso, A. A., Callander, N. S., Mateos Manteca, M. V., Reddy, N., Hakim, S., Patel, N., Williams, D., Jewell, R. C., Zhou, X., Gupta, I., Nooka, A. K.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
PB2014: TECLISTAMAB VS SELINEXOR‐DEXAMETHASONE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING‐ADJUSTED INDIRECT COMPARISON
Rosinol, L., Usmani, S. Z., Bahlis, N., Krishnan, A. Y., Nooka, A. K., Oriol, A., Delforge, M., Garfall, A. L., Donk, N. W., Rodríguez Otero, P., Martin, T. G., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Moreau, P.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P922: HEALTH‐RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1
Popat, R., Moreau, P., Usmani, S. Z., Garfall, A., Mateos, M.‐V., San‐Miguel, J. F., Oriol, A., Nooka, A. K., Rosinol, L., Chari, A., Karlin, L., Krishnan, A., Bahlis, N., Martin, T., Besemer, B., Martínez‐López, J., Delforge, M., Fastenau, J., Gries, K. S., Donk, N. W.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1
Martínez‐López, J., Moreau, P., Usmani, S. Z., Garfall, A., Donk, N. W., San‐Miguel, J. F., Oriol, A., Chari, A., Karlin, L., Mateos, M.‐V., Popat, R., Nooka, A. K., Sidana, S., Trancucci, D., Verona, R., Girgis, S., Uhlar, C., Stephenson, T., Banerjee, A., Krishnan, A.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
Sonneveld, P, Chanan‐Khan, A, Weisel, K, Nooka, AK, Masszi, T, Beksac, M, Spicka, I, Hungria, V, Munder, M, Mateos, MV, Mark, TM, Levin, MD, Ahmadi, T, Qin, X, Garvin Mayo, W, Gai, X, Carey, J, Carson, R, Spencer, A
Published in HemaSphere (01.04.2022)
Published in HemaSphere (01.04.2022)
Get full text
Journal Article
Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial
PATT, Yehuda Z, HASSAN, Manal M, LOZANO, Richard D, NOOKA, Ajay K, SCHNIRER, Isaac I, ZELDIS, Jerome B, ABBRUZZESE, James L, BROWN, Thomas D
Published in Cancer (15.02.2005)
Published in Cancer (15.02.2005)
Get full text
Journal Article
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy
Hoff, A. O., Toth, B. B., Altundag, K., Guarneri, V., Adamus, A., Nooka, A. K., Sayegh, G. G., Johnson, M. M., Gagel, R. F., Hortobagyi, G. N.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
Weisel, K., Palumbo, A., Chanan-Khan, A., Nooka, A.K., Spicka, I., Masszi, T., Beksac, M., Hungria, V., Munder, M., Mateos, M.-V., Mark, T.M., Spencer, A., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Sonneveld, P.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents
Mina, Roberto, Joseph, Nisha S., Kaufman, Jonathan L., Gupta, Vikas A., Heffner, Leonard T., Hofmeister, Craig C., Boise, Lawrence H., Dhodapkar, Madhav V., Gleason, Charise, Nooka, Ajay K., Lonial, Sagar
Published in Cancer (01.02.2019)
Published in Cancer (01.02.2019)
Get full text
Journal Article